Supramolecular Chemistry Enables Radiolabeling of Proteins under Mild Conditions
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c01339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Romane Vizier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Université Bourgogne Europe, CNRS, Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB, UMR CNRS 6302), 9 Avenue Alain Savary, 21078 D…. Hauptthemen laut MEDLINE: Trastuzumab, Radiopharmaceuticals. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, European Commission, Centre National de la Recherche Scientifique.
Abstract (Originalsprache)
Monoclonal antibodies have proven to be highly effective for in vivo targeting in nuclear medicine applications. However, typical radiolabeling methods, for PET/SPECT imaging and targeted radionuclide therapy, often require conditions that may affect the structural integrity of these fragile biomolecules. In this study, we introduce a novel methodology, based on supramolecular chemistry, for efficient radiolabeling of antibodies under mild conditions. Specifically, we report the synthesis of DOTA-cucurbit[7]uril (DOTA-CB[7]), a precursor that can be readily radiolabeled with a variety of radionuclides (111In, 68Ga, 89Zr, 177Lu, 225Ac). [111In]In-DOTA-CB[7] was conjugated to an anti-HER2 antibody (trastuzumab) site─specifically grafted with adamantan-1-amine groups. The supramolecular conjugation, driven by the exceptionally strong affinity between CB[7] and adamantan-1-amine enabled rapid and efficient formation of a stable antibody-radiometal complex under mild conditions. The resulting radioimmunoconjugate demonstrated high in vitro and in vivo stability and effective targeting of HER2+ tumors, as evidenced by SPECT/CT imaging in mice xenografted with HER2+ SKOV-3 cells. These findings highlight the potential of DOTA-CB[7] for supramolecular radiolabeling, offering a simple and versatile alternative to traditional covalent approaches, particularly for applications requiring compatibility with heat-sensitive biomolecules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Bourgogne Europe, CNRS, Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB, UMR CNRS 6302), 9 Avenue Alain Savary, 21078 Dijon Cedex, France.
- Department of Medical Imaging, Nuclear Medicine, Radboudumc, 6525 GA, Nijmegen, The Netherlands.
- CheMatech, 2 Rue Pauline Kergomard, F-21000 Dijon, France.
ORCID-Profile: Romane Vizier, Franck Denat, Sanne A M van Lith, Victor Goncalves
Förderung
- Agence Nationale de la Recherche
- European Commission
- Centre National de la Recherche Scientifique
- Conseil r?gional de Bourgogne-Franche-Comt?
- Universit? Bourgogne Europe
Zitieren
APA
Vizier, R., Boswinkel, M., Moreau, M., Faivre, J., Carrierre, M., Cheveau, M., Poty, S., Denat, F., van Lith, S. A. M., & Goncalves, V. (2025). Supramolecular Chemistry Enables Radiolabeling of Proteins under Mild Conditions. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01339
Vancouver
Vizier R, Boswinkel M, Moreau M, Faivre J, Carrierre M, Cheveau M, et al. Supramolecular Chemistry Enables Radiolabeling of Proteins under Mild Conditions. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c01339
BibTeX
@article{Vizier2025,
author = {Vizier, Romane and Boswinkel, Milou and Moreau, Mathieu and Faivre, Johan and Carrierre, Manon and Cheveau, Maxime and Poty, Sophie and Denat, Franck and van Lith, Sanne A M and Goncalves, Victor},
title = {Supramolecular Chemistry Enables Radiolabeling of Proteins under Mild Conditions},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c01339}
}
EUVIMED